MENU
+Compare
LLY
Stock ticker: NYSE
AS OF
Aug 15 closing price
Price
$701.23
Change
+$16.80 (+2.45%)
Capitalization
628.62B

LLY stock forecast, quote, news & analysis

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology... Show more

LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. LLY showed earnings on August 07, 2025. You can read more about the earnings report here.
A.I.Advisor
a Summary for LLY with price predictions
Aug 15, 2025

LLY's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for LLY moved out of oversold territory on August 13, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In of the 27 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 51 cases where LLY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in of 369 cases, the price rose further within the following month. The odds of a continued upward trend are .

LLY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 330 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 05, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LLY turned negative on July 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

LLY moved below its 50-day moving average on July 29, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LLY crossed bearishly below the 50-day moving average on August 06, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LLY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (34.364) is normal, around the industry mean (9.409). LLY has a moderately high P/E Ratio (45.832) as compared to the industry average of (23.546). Projected Growth (PEG Ratio) (1.015) is also within normal values, averaging (1.848). LLY has a moderately low Dividend Yield (0.008) as compared to the industry average of (0.027). LLY's P/S Ratio (11.876) is very high in comparison to the industry average of (3.361).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

LLY is expected to pay dividends on September 10, 2025

Eli Lilly & Co LLY Stock Dividends
A dividend of $1.50 per share will be paid with a record date of September 10, 2025, and an ex-dividend date of August 15, 2025. The last dividend of $1.50 was paid on June 10. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 87.45B. The market cap for tickers in the group ranges from 72.83K to 628.62B. LLY holds the highest valuation in this group at 628.62B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 3%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 13%. SCLX experienced the highest price growth at 15%, while CHGCF experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 69
Price Growth Rating: 51
SMR Rating: 62
Profit Risk Rating: 80
Seasonality Score: -16 (-100 ... +100)
View a ticker or compare two or three
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Lilly Corporate Center
Phone
+1 317 276-2000
Employees
43000
Web
https://www.lilly.com